Adenomyosis: Genomic Mechanisms and Biological Response

NCT03428854 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2021-02-02

No results posted yet for this study

Summary

Examination of genomic and biologic responses to LNG-IUS in patients with adenomyosis.

Conditions

  • Adenomyosis
  • Abnormal Uterine Bleeding

Interventions

DRUG

LNG-IUS

Levnorgestrel containing IUD

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2022-10-01
Completion
2022-10-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03428854 on ClinicalTrials.gov